MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
InfuSystem Holdings Gross Profit 2011-2026 | INFU
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit InfuSystem Holdings
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 62.6 M | 60.2 M | 58.8 M | 46.9 M | 39 M | 43.4 M | 44.7 M | 51.2 M | 47.4 M | 43.7 M | 42.9 M | 35.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 62.6 M | 35.4 M | 48 M |
Quarterly Gross Profit InfuSystem Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20.8 M | 19.9 M | 19.2 M | - | 19 M | 16.7 M | 16.5 M | - | 15.6 M | 15.8 M | 15 M | - | 16.2 M | 14.9 M | 15.4 M | - | 15.3 M | 15 M | 14.6 M | - | 15.1 M | 16 M | 12.7 M | - | 12.2 M | 11.4 M | 10.3 M | - | 9.67 M | 9.69 M | 10.2 M | - | 11 M | 10.3 M | 10.6 M | - | 10.4 M | 11.1 M | 12.6 M | 13.2 M | 12.9 M | 11.6 M | 11.9 M | - | 11.7 M | 11.9 M | 12.1 M | - | 11.3 M | 10.3 M | 10.4 M | - | 10.2 M | 10.3 M | 10.4 M | - | 9.23 M | 8.99 M | 9.05 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 20.8 M | 8.99 M | 13 M |
Gross Profit of other stocks in the Medical instruments industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
62.4 K | - | - | $ 810 M |  USA |
 |
Baxter International
BAX
|
959 M | $ 19.51 | 2.12 % | $ 9.95 B | USA |
 |
Becton, Dickinson and Company
BDX
|
8.29 B | $ 195.0 | 0.49 % | $ 56.1 B | USA |
 |
Luminex Corporation
LMNX
|
248 M | - | - | $ 1.75 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
9.51 M | $ 8.13 | -5.9 % | $ 164 M | USA |
 |
Akers Biosciences, Inc.
AKER
|
479 K | - | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
86.5 M | - | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
436 M | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
1.68 M | - | - | $ 282 M | USA |
 |
Harvard Bioscience
HBIO
|
66.1 M | $ 0.66 | -0.9 % | $ 28 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
1.48 B | - | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
1.38 B | - | -0.02 % | $ 16.3 B | USA |
 |
Repro Med Systems
KRMD
|
16.7 M | $ 5.58 | -3.96 % | $ 254 M | USA |
 |
Alcon
ALC
|
5.51 B | $ 77.69 | -1.42 % | $ 40.4 B |  Schweiz |
 |
AtriCure
ATRC
|
348 M | $ 39.19 | -0.94 % | $ 1.84 B | USA |
 |
Merit Medical Systems
MMSI
|
643 M | $ 86.9 | -1.41 % | $ 5.06 B | USA |
 |
ICU Medical
ICUI
|
825 M | $ 139.1 | -2.5 % | $ 3.39 B | USA |
 |
electroCore
ECOR
|
13.2 M | $ 4.54 | 1.23 % | $ 25 K | USA |
 |
iRhythm Technologies
IRTC
|
408 M | $ 175.59 | -1.04 % | $ 5.48 B | USA |
 |
AngioDynamics
ANGO
|
158 M | $ 12.64 | -1.56 % | $ 516 M | USA |
 |
Isoray
ISR
|
817 K | - | 0.03 % | $ 108 M | USA |
 |
The Cooper Companies
COO
|
2.68 B | $ 81.37 | -0.72 % | $ 16.2 B | USA |
 |
Nephros
NEPH
|
8.4 M | $ 4.78 | -2.15 % | $ 49.6 M | USA |
 |
Glaukos Corporation
GKOS
|
239 M | $ 111.02 | -1.67 % | $ 5.38 B | USA |
 |
LeMaitre Vascular
LMAT
|
151 M | $ 80.78 | -0.39 % | $ 1.81 B | USA |
 |
Haemonetics Corporation
HAE
|
749 M | $ 80.15 | - | $ 4.03 B | USA |
 |
Masimo Corporation
MASI
|
1 B | $ 127.63 | -1.87 % | $ 6.8 B | USA |
 |
Intuitive Surgical
ISRG
|
5.63 B | $ 562.18 | -0.74 % | $ 200 B | USA |
 |
OraSure Technologies
OSUR
|
79.4 M | $ 2.37 | -2.27 % | $ 176 M | USA |
 |
Microbot Medical
MBOT
|
117 K | $ 2.09 | 4.69 % | $ 21.3 M |  Israel |
 |
Milestone Scientific
MLSS
|
6.43 M | $ 0.29 | 6.23 % | $ 23.1 M | USA |
 |
STERIS plc
STE
|
2.4 B | $ 251.21 | -0.91 % | $ 24.8 B | USA |
 |
NeuroMetrix
NURO
|
1.68 M | - | 5.05 % | $ 9.02 M | USA |
 |
Envista Holdings Corporation
NVST
|
1.37 B | $ 21.74 | 0.09 % | $ 3.74 B | USA |
 |
Stereotaxis
STXS
|
14.9 M | $ 2.32 | 0.65 % | $ 187 M | USA |
 |
Pro-Dex
PDEX
|
19.5 M | $ 37.63 | -2.21 % | $ 124 M | USA |
 |
Predictive Oncology
POAI
|
798 K | - | - | $ 32.4 M | USA |
 |
Utah Medical Products
UTMD
|
7.1 M | $ 57.34 | 2.47 % | $ 208 M | USA |
 |
ResMed
RMD
|
2.02 B | $ 245.02 | 1.75 % | $ 35.8 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
1.96 B | $ 11.33 | -0.87 % | $ 2.3 B | USA |
 |
Repligen Corporation
RGEN
|
151 M | $ 163.5 | -0.22 % | $ 9.11 M | USA |
 |
BioLife Solutions
BLFS
|
18.6 M | $ 23.86 | -1.32 % | $ 1.1 B | USA |
 |
Retractable Technologies
RVP
|
-1.03 M | $ 0.77 | -0.7 % | $ 23.1 M | USA |
 |
STAAR Surgical Company
STAA
|
240 M | $ 23.45 | 1.56 % | $ 1.15 B | USA |
 |
Teleflex Incorporated
TFX
|
1.7 B | $ 123.04 | 0.79 % | $ 5.76 B | USA |
 |
West Pharmaceutical Services
WST
|
998 M | $ 276.44 | 0.44 % | $ 20.2 B | USA |